Patent ID: 7629333

Claim:
A method for protecting against the adverse effects which arise during the use of chemotherapy or radiation therapy in the treatment of cancer comprising administering to a subject an amorphous a dosage form of amifostine which comprises sterile, amorphous amifostine which is suitable for reconstitution with a pharmaceutically-acceptable vehicle into an injectable particulate-free drug product for parental administration to a subject, wherein said amorphous amifostine forms: (a) less than about 5 weight percent of 2-[(3aminopropyl)amino]ethane thiol when maintained at a temperature of about 40° C. for about one week; (b) less than about 5 weight percent of 2-[(3aminopropyl)amino]ethane thiol when maintained at a temperature of about 25° C. for about one month; or (c) less than about 3 weight percent of 2-[(3aminopropyl)amino]ethane thiol when maintained at a temperature of about 5° C. for about two years; thereby protecting against the adverse effects which arise during the use of chemotherapy or radiation therapy in the treatment of cancer.